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Abstract Tourette syndrome is a neuropsychiatric condition
characterized by both motor and phonic tics over a period of at
least 1 year with the onset in childhood or adolescence. Apart
from the tics, most of the patients with Tourette syndrome
have associated neuropsychiatric comorbidities consisting of
attention deficit hyperactivity disorder, obsessive compulsive
disorder, rage attacks, sleep issues, depression, and migraine.
Patients may also have physical complications directly from
violent motor tics which can rarely include cervical myelopa-
thy, arterial dissection, and stroke. The purpose of this article
is to review the associated neuropsychiatric comorbidities of
Tourette syndrome with emphasis on recent research.
Keywords Tourette syndrome (TS) . Neuropsychiatric
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Introduction
Gilles de la Tourette syndrome (TS) is a neuropsychiatric con-
dition characterized by both motor and phonic tics with the
onset in childhood or adolescence. First described by French
physician Georges Gilles de la Tourette in 1885, it is consid-
ered to be as one of the most common childhood movement
disorders. As per the Diagnostic and Statistical Manual of
Mental Disorders Fifth Edition’s (DSM-V), TS is diagnosed
clinically by the presence of multiple motor and one or more
phonic tics, lasting at least 1 year with the onset prior to age 18
[1]. TS is commonly diagnosed between 2 and 15 years of age
with the mean age of onset is 5–7 years. A tic is a brief ste-
reotypic paroxysmal motor activity or vocalization which is
often preceded by a premonitory urge or sensation [2].
BPremonitory urges^ are a cardinal feature of tics; however,
it is often difficult to elicit this history in younger children.
Other characteristics of tics include suppressibility, suggest-
ibility, and distractibility which may mimic Bpsychogenic
movement disorder^ and can lead to a wrong diagnosis [3].
Tics can be very variable, with typically a waxing and waning
course; however, severity typically peaks during early teenage
years. Tics typically start as simple tics and become more
complex over the time. Motor tics typically predate vocal tics.
Tics typically tend to abate in most patients by late teenage or
adult years.
The epidemiology of TS is variable depending on the pop-
ulation studied. In one study, the prevalence of TS in a pooled
population was reported to be 0.52 % (with 95 % confidence
interval 0.32–0.85). TS more commonly affects males than
females (ratio of approximately 4:1) [4]. The prevalence of
comorbidities was 85.7%. Over 70% of patients had attention
deficit hyperactivity disorder or obsessive compulsive disor-
der, and in around 30 % of the patients, mood, anxiety, and
disruptive behavior were reported [5]. There are rare but seri-
ous cases of associated cervical myelopathy, stroke, and dis-
section secondary to violent motor tics [6]. There have also
been reports of increased prevalence of migraine in patients
with TS [7].
The exact pathophysiology of TS is unclear at this point.
Various hypotheses have been postulated. It is considered to
be a complex disorder, thought to be the effect of environment
(infection, autoimmunity as well as perinatal problems) in a
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genetically predisposed individual. In one study, TS pa-
tients were found to have decreased gray matter thick-
ness in the pre- and post-central and internal, inferior,
and superior frontal sulci that correlated with clinical
severity of the tics [8]. Various other studies suggested
that TS is due to dysfunction in the cortico-striato-
thalamo-cortical circuit [9–11]. The cause of the dysfunc-
tion in the cortico-basal ganglia structures is not clearly
defined; however, abnormalit ies of the gamma-
aminobutyric acid (GABA) pathway are postulated to
cause the disinhibition seen in TS patients [12]. To sim-
plify, the basal ganglia (caudate, striatum, and globus
pallidus) is involved in the control of voluntary move-
ments and abnormalities affecting these areas result in a
variety of movement disorders including TS.
The genetics of TS is still under investigation. TS is
postulated to be a familial disorder, likely with bilinear
inheritance (both parents affected) [13]. One study noted
an overall heritability of 0.77 in tic disorders, greatest for
first degree relatives [14]. Despite advancement in genetic
studies, a single causative gene has not been found [15].
Studies have found an association between TS and hista-
mine decarboxylase (HDC) gene [16, 17]. L-histamine
decarboxylase, encoded by HDC gene, is the rate limiting
enzyme in histamine synthesis. In addition, there may be
some association of various single nucleotide polymor-
phisms (SNPs) noted by genome wide association studies
(GWAS) involving proteins encoding axon guidance and
outgrowth in the developing striatum [18].
In this review, we discuss the various neuropsychiatric co-
morbidities seen in TS patients. These comorbid conditions
are often the main source of impairment in the TS patients and
compromise overall well-being much more than the tic sever-
ity. Because of this high rate of comorbidity, any patient pre-
senting with tics should have a thorough investigation for
associated comorbidities.
Attention Deficit Hyperactivity Disorder Attention deficit
hyperactivity disorder (ADHD) is a complex neurobiological
disorder, characterize by symptoms of inattention and
hyperactivity/impulsivity [19]. It is the most common comor-
bidity in the TS patients, ranging between 60 and 80 % de-
pending on the type of patient population studied [20, 21].
ADHD symptoms precede the onset of tics by 2–3 years and
begin around the age of 3–5 years. The hyperactive subtype is
predominant in the younger patients, whereas inattentive type
is more common in adult patients, who also have higher risk of
substance misuse and aggressive behavior [22, 23]. The path-
ogenesis of ADHD in TS patients is complex and includes
environmental, genetic, and neurobiological factors [24, 25].
Abnormal level of neurotransmitters (dopamine and gluta-
mate) along with loss of normal globus pallidus symmetry is
reported in both [26]. The exact genetic mechanism is yet to
be elucidated; however, multiple genes have been postulat-
ed in the pathogenesis of ADHD in TS patients, which
includes catechol-O-methyltransferase (COMT), dopamine
receptor D2 (DRD2), monoamine oxidase A (MAOA), sol-
ute carrier family 6, member 4 (SLC6A4), myelin-
associated oligodendrocyte basic protein (MOBP), dopa-
mine receptor D1 (DRD1), and fatty acid desaturase 2
(FASD2) [27, 28]. The most important neurobiological net-
work involved in pathogenesis is the cortico-striato-
thalamo-cortical circuit, which is implicated in tic genera-
tion and in impulsivity as seen in ADHD patients [26, 29].
Studies have suggested an involvement of the basal ganglia
circuit, especially hypo functioning of the direct pathway
resulting in abnormal behavior causing problems with sus-
taining attention and impulsive action [29]. The treatment
of ADHD in TS patients is multimodal and includes a com-
bination of psychoeducation to the patient and family, cog-
nitive behavioral therapy, and pharmacological interven-
tions. Three classes of medications are commonly used
for the treatment of ADHD in TS patients, including stim-
ulants (methylphenidate, dextroamphetamine), alpha-
agonists (clonidine, guanfacine), and norepinephrine reup-
take inhibitors (atomoxetine). In the past, there has been
concern regarding the effect of stimulant treatment on the
exacerbation of tics. However, recent studies have shown
beneficial effect of stimulants in TS patients with comorbid
ADHD symptoms [30]. Alpha-2 agonist (clonidine,
guanfacine) are considered to be the first line treatment
given proven efficacy for both tics and ADHD symptoms.
Stimulants are suggested to be the second line of treatment,
especially useful in children requiring immediate relief of
ADHD symptoms, while it has a very little evidence to
support for the treatment of the tics, and in-fact, there is
concern about precipitating tics in some patients. More re-
cently, the partial dopamine agonist (aripiprazole) has been
recommended for the treatment if TS with mild ADHD
symptoms [31]. A non-invasive modality known as repeti-
tive transcranial magnetic stimulation (rTMS), in which
changing magnetic fields stimulate targeted areas of the
brain, shown to alter cortical activity, has been tried for
the treatment of ADHD and TS, with conflicting results
and further investigations have been suggested [32, 33].
Obsessive Compulsive Disorder Obsessive compulsive dis-
order (OCD) is defined by the presence of obsessions (intru-
sive thoughts) and compulsions (repetitive behavior) leading
to adaptive malfunctioning and emotional maladjustment
[34]. The prevalence of OCD ranges from 11 to 80 % of
patients with TS [35]. The exact etiology of OCD in TS pa-
tients is unclear; however, studies have suggested an involve-
ment of the basal ganglia circuit, especially disruption of the
indirect pathway resulting in repetitive behaviors and
thoughts. [29]. OCD symptoms have been reported to arise
218 Curr Dev Disord Rep (2016) 3:217–221
any time during the course of TS. Interestingly, compulsive
symptoms were more common than obsessions if OCD is the
presenting symptom in TS patients [36]. The presentation of
OCD symptoms in TS patients can be different than the typ-
ical presentation of patients with primary OCD. For example,
TS patients are reported to have greater rates of symmetric
obsession, obsessional counting (arithmomania), and Bjust
right^ perception, whereas primary OCD patients reports
higher prevalence of cleaning rituals, compulsive washing,
and fears of contaminations [55]. Treatment of OCD in TS
patients is multimodal including cognitive behavioral therapy
and pharmacotherapy. Recommended pharmacotherapy can
include atypical antipsychotics (risperidone) combined with
a selective serotonin reuptake inhibitor (SSRI) [37].
Thalamic deep brain stimulation has been suggested in select-
ed cases of refractory TS with comorbid OCD; however,
existing data is inconclusive, and the procedure remains ex-
perimental [56].
Rage Attacks Twenty-five to seventy-five percent of TS pa-
tients have episodic behavioral outburst and anger issues [38].
There has been a significantly increased prevalence of impulse
control disorder (especially intermittent explosive disorder) in
adult TS patients. Atypical antipsychotic (risperidone) have
been reported to be effective in reducing the intensity and
frequency of the rage attacks [39].
Depression Thirteen to seventy-six percent of patients with
TS reported to have depressive symptoms [40]. The mecha-
nism of development of depression is multifactorial including
a psychological reaction to potentially disabling condition and
associated social stigma (many children experience bullying,
teasing, and receive derogatory nicknames) and multiple neu-
rotransmitter abnormalities and potential side effect of medi-
cations commonly used to treat tics (especially neuroleptics).
Selective serotonin reuptake inhibitors and tricyclic antide-
pressants have been reported to be effective in the treatment
of depression in TS patients [41].
Sleep Issues Twelve to sixty-two percent of patients with TS
have been reported to have various sleep problems including
REM (nightmares), NREM sleep disorders (night terrors,
somnambulism), trouble initiating sleep, and restlessness
[42]. Clonidine and melatonin have been reported to be effec-
tive in these patients [43].
Migraine In a study done by Kwak et al., 25 % of TS patients
satisfied the diagnostic criteria of migraine compared to 10–
13 % of general adult population with p value of <.001 and
concluded that migraine is an another comorbidity in TS pa-
tients [7]. There was a very similar observation made by
Barabas et al., who reported that 27 % of patients with TS
met the diagnostic criteria for migraine headache [44]. The
mechanism is unclear; however, a defect in the serotonin me-
tabolism has been postulated [45].
Learning Disabilities In a large study (n = 5450), 23 % of
patients with TS had associated learning disabilities [46],
whereas older studies with small patient population have re-
ported even higher prevalence (50 %) of learning disabilities
(LD) [47]. Learning disability was more common in males
than females (p < .001). Patients with learning disability also
had increased rates of other comorbid conditions, most nota-
bly ADHD (80 % of patients with TS and LD). This study
suggested that ADHD could be a causal factor or a confounder
for the diagnosis of LD as only 11 % of the TS children
without ADHD had LD [46]. Learning disabilities in math
and spelling are the most frequent. The patients also have
increased rate of reading disorder. In most patients, LD is
present by the time TS is diagnosed, and therefore, patients
need to be evaluated by neuropsychological testing so that
they can receive appropriate educational accommodations.
Rare Neurological Complications TS can rarely be associ-
ated with more severe complications which include cervical
myelopathy, cervical disk herniation, compressive neuropa-
thy, stroke, and arterial dissection [48–53]. Patterson et al.
recently published four cases of cervical myelopathy and ar-
terial dissection, leading to spinal cord injury and stroke sec-
ondary to violent motor tics involving the neck in patients
with TS. They suggested aggressive treatment of violent tics
to prevent these dreaded complications and recommended
using cervical collar for stabilization and prevention of initial
injury and to halt progression of existing injury [6]. Termine
et al. suggested treatment with botulinum toxin to prevent
these severe complications [54]. In these cases, the comorbid-
ities are complications of the actual physical tics rather than
neuropsychiatric complications arising from a parallel, sec-
ondary, or associated neurochemical phenomenon.
Approach to the Patient with a Tic Disorder
Patients with tics disorders are often focused on the involun-
tary movements or noises that bring them to medical attention.
The diagnosis of a tic disorder is often made without much
difficulty, and when the criteria for symptom complexity and
duration are met, the diagnosis of Tourette syndrome is ap-
plied. However, a thorough knowledge of the comorbidities
often associated is essential in the evaluation and longitudinal
care of these patients. Patients and families may be unaware or
minimize neuropsychiatric comorbidities, and specific inquiry
and investigation are often quite rewarding and guides treat-
ment. The conditions which are causing the most distress and
alteration in life quality are given priority in the treatment
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plan, and very often, these are not the motor tics which may
have brought the patient initially to medical attention.
Conclusion
Tourette syndrome is a complex neuropsychiatric disorder
with tics (both motor and phonic), and a variety of neuropsy-
chiatric comorbidities more commonly includes ADHD,
OCD, impulse control disorder, rage attacks, sleep issues, de-
pression, migraine and rarely cervical myelopathy, stroke, and
dissection due to violent motor tics. The pathophysiology re-
lating to comorbidities in TS is unclear, however thought to be
at least in part related to dysfunction in the cortico-striato-
thalamo-cortical circuit. Investigation and treatment of comor-
bid conditions are an essential part of the treatment plan for all
patients with TS. Practitioners should also be aware about the
rare but severe neurological complications in these patients
and consider treating tics aggressively.
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